Skip to main content

Larimar Therapeutics, Inc.

corporate_fare Company Profile

Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed LRMR - Latest Insights

LRMR
Apr 20, 2026, 4:06 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Shareholders to Vote on 100 Million Share Increase, Doubling Authorized Common Stock
Sentiment: Negative
View Wiseek Article
LRMR
Apr 10, 2026, 4:09 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Larimar Therapeutics Seeks Shareholder Approval to Double Authorized Common Stock
Sentiment: Negative
View Wiseek Article
LRMR
Mar 19, 2026, 3:41 PM EDT
Filing Type: 10-K
Importance Score:
8
Larimar Therapeutics Secures Breakthrough Therapy Designation, FDA Alignment on Surrogate Endpoint, and $107.6M Funding for Nomlabofusp
Sentiment: Positive
View Wiseek Article
LRMR
Mar 19, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
8
Larimar Therapeutics Secures Breakthrough Therapy Designation, Confirms June 2026 BLA Submission, and Extends Cash Runway
Sentiment: Positive
View Wiseek Article
LRMR
Mar 19, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Breakthrough Therapy Designation, Extended Cash Runway Highlight Larimar's Q4 Report
Sentiment: Positive
View Wiseek Article
LRMR
Mar 09, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
8
Larimar Therapeutics Sets June 2026 BLA Target for Nomlabofusp, Q2 Topline Data Expected
Sentiment: Positive
View Wiseek Article
LRMR
Mar 09, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
8
Larimar Therapeutics Updates on Nomlabofusp BLA Path and Extends Cash Runway into Q2 2027
Sentiment: Positive
View Wiseek Article
LRMR
Mar 02, 2026, 7:46 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Deerfield Management Increases Stake in Larimar Therapeutics with $25 Million Offering Participation
Sentiment: Positive
View Wiseek Article
LRMR
Mar 02, 2026, 7:46 PM EST
Filing Type: 4
Importance Score:
9
Deerfield Management Makes $25M Open Market Purchase in Larimar Therapeutics
Sentiment: Positive
View Wiseek Article
LRMR
Feb 26, 2026, 4:20 PM EST
Filing Type: 424B5
Importance Score:
9
Larimar Therapeutics Prices $100M Public Offering at 16% Discount to Fund Breakthrough Therapy Development
Sentiment: Neutral
View Wiseek Article
LRMR
Feb 25, 2026, 4:05 PM EST
Filing Type: 424B5
Importance Score:
8
Larimar Therapeutics Launches $75M Public Offering to Fund Breakthrough Therapy Development Amidst Going Concern Risk
Sentiment: Neutral
View Wiseek Article
LRMR
Feb 24, 2026, 7:02 AM EST
Filing Type: 8-K
Importance Score:
9
FDA Grants Breakthrough Therapy Designation for Nomlabofusp in Friedreich's Ataxia, De-risking Regulatory Path
Sentiment: Positive
View Wiseek Article
LRMR
Jan 22, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Larimar Therapeutics Restructures Major Investor's Common Stock into Convertible Preferred Shares
Sentiment: Neutral
View Wiseek Article
LRMR
Jan 12, 2026, 4:18 PM EST
Filing Type: 8-K
Importance Score:
8
Larimar Therapeutics Reports Strong Cash Position and Positive Nomlabofusp Clinical Data, Targets Q2 2026 BLA Submission
Sentiment: Positive
View Wiseek Article